VYGR Stock Overview
A biotechnology company, focuses on the human genetics for the cure of neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Voyager Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.17 |
| 52 Week High | US$9.55 |
| 52 Week Low | US$2.75 |
| Beta | 1.02 |
| 1 Month Change | -18.72% |
| 3 Month Change | -39.96% |
| 1 Year Change | -62.40% |
| 3 Year Change | -64.46% |
| 5 Year Change | -68.92% |
| Change since IPO | -82.14% |
Recent News & Updates
Recent updates
Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump
Feb 25
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Jan 30
Developing Tau-Targeting Therapies Will Open Doors But May Encounter Setbacks
Jan 26 Strong partnerships and collaborations are expected to enhance revenue and earnings through milestone payments and shared R&D efforts.Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral
Nov 18Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified
Oct 17Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
Aug 26Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 09Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S
Aug 08Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
Jun 05There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Mar 15Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Mar 08What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Mar 04Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Jan 04Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target
Oct 04Voyager Therapeutics hires new finance chief
Sep 07Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02
Aug 04Shareholder Returns
| VYGR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.6% | 0.5% | 5.4% |
| 1Y | -62.4% | -11.9% | 3.6% |
Return vs Industry: VYGR underperformed the US Biotechs industry which returned -11.9% over the past year.
Return vs Market: VYGR underperformed the US Market which returned 3.6% over the past year.
Price Volatility
| VYGR volatility | |
|---|---|
| VYGR Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: VYGR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VYGR's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 172 | Al Sandrock | www.voyagertherapeutics.com |
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company’s lead clinical candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes VY1706, tau silencing gene therapy in preclinical trial for treatment of alzheimer’s disease; SOD1 silencing gene therapy program for the treatment of ALS in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial.
Voyager Therapeutics, Inc. Fundamentals Summary
| VYGR fundamental statistics | |
|---|---|
| Market cap | US$175.01m |
| Earnings (TTM) | -US$65.00m |
| Revenue (TTM) | US$80.00m |
2.2x
P/S Ratio-2.7x
P/E RatioIs VYGR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VYGR income statement (TTM) | |
|---|---|
| Revenue | US$80.00m |
| Cost of Revenue | US$127.37m |
| Gross Profit | -US$47.37m |
| Other Expenses | US$17.64m |
| Earnings | -US$65.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | -59.21% |
| Net Profit Margin | -81.25% |
| Debt/Equity Ratio | 0% |
How did VYGR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 14:57 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Voyager Therapeutics, Inc. is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jack Allen | Baird |
| Aydin Huseynov | Benchmark Company |